EX-10.2
Adaptive Biotechnologies Corp
WAIVER AGREEMENT
This WAIVER AGREEMENT (this “Waiver”) is entered into as of June 15, 2026, by and among Adaptive Biotechnologies Corporation, a Washington corporation (the “Company”), OrbiMed Royalty & Credit Opportunities IV, LP, a Delaware limited partnership, in its capacity as Purchaser Agent and as a Purchaser (in such capacities, “OrbiMed”), and each other Purchaser party hereto (OrbiMed, together with such other Purchasers, the “Waiving Parties”).
RECITALS
A. The Company, OrbiMed (as Purchaser Agent) and the Purchasers are parties to that certain Revenue Interest Purchase Agreement, dated as of September 12, 2022 (as amended, supplemented or otherwise modified from time to time, the “Purchase Agreement”). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Purchase Agreement.
…